[其他] AZ更新美國第三期臨床數據:保護力約76%
-------------------------------------------------------------------------
1.發文前請先詳閱[其他]分類發文規範,未依規範發文將受處份。
----------------------------按ctrl+y可刪除以上內容。---------------------
76% vaccine efficacy against symptomatic COVID-19
100% efficacy against severe or critical disease and hospitalisation
85% efficacy against symptomatic COVID-19 in participants aged 65 years and over
Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021.
These results have been presented to the independent Data Safety Monitoring Board. The primary analysis is pre-specified in the protocol and will be the basis for a regulatory submission for Emergency Use Authorization to the US Food and Drug Administration in the coming weeks.
This primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from the 32,449 trial participants, an additional 49 cases to the previously announced interim analysis. Participants were randomised on a 2:1 ratio between the vaccine and placebo group.
The primary endpoint, vaccine efficacy at preventing symptomatic COVID-19 was 76% (confidence interval (CI): 68% to 82%) occurring 15 days or more after receiving two doses given four weeks apart. In addition, results were comparable across age groups, with vaccine efficacy of 85% (CI: 58% to 95%) in adults 65 years and older. A key secondary endpoint, preventing severe or critical disease and hospitalisation, demonstrated 100% efficacy. There were eight cases of severe COVID-19 observed in the primary analysis with all of those cases in the placebo group.
The vaccine was well tolerated, and no safety concerns related to the vaccine were identified.
被美國監管單位刁了一下
更新了數據
針對有症狀的保護力:76%
針對預防重症跟住院的保護力:100%
針對65歲以上有症狀的保護力:85%
與禮拜一公布的期中報告接近
總共32499位參與者
有190位有症狀者
比期中報告中的人數增加49位
AZ疫苗安全有效
--
中国疫苗要打3針
反正就是接近80% 誰叫陳時中堅持不買輝瑞的
人家代理亞洲區也要拒買 真是腦子壞了
陳有堅持不買輝瑞? 代理問題不是BNT嗎?
阿幹看錯隻
把AZ講的跟科興的是誰啊…
看大家要相信數據相信專業的人,還是要相信無腦起鬨
帶風向的人?
輝瑞保存也很難啊 超低溫
不差了, 但有95%的, 誰想打75的呢
但AZ對非洲的大概只有10%, 滿慘的
支那科興讚讚讚 支那gn最喜歡
Az 夠便宜和運送方便。
還是輸給嬌生 輝瑞 莫德納 只贏中國科科
可以打一劑誰要兩劑
嬌生疫苗VE=66%,雖然只要一劑,但這個輸贏要怎麼
比?
死掉當然就不會感染病毒了
嬌生對變種病毒比較強且報告完整
BNT有中資不好買就算了,台灣五月就能拿到莫德納,
民眾要快點習慣台灣有本土確診
對於Novavax和強生,針對B.1.351的功效均降至60%以
下。該疫苗針對變種毒株的真正功效尚不清楚,因為他
們測試了原始變種和新變種的混合。
針對南非變異株的試驗還沒多少完整的報告,嬌生也一
樣,試驗當下不同病毒株流行的程度不同,就會影響
整體結果。下降是一定的,但下降到多少,目前就AZ
很明確"無效",其他幾家只有中和抗體的結果
95%的比較貴
BNT還要冷鏈 又不是功能最強就賣最好
德國打BNT疫苗,最近疫情卻升高
德國截至22日,過去一周每10萬人有107人確診,超出
重症加護病房負荷門檻。
5
Re: [新聞] 高端發表二期試驗期中分析數據 預期保護說的應該是這一篇 其中的這一段 the predicted vaccine efficacy is between 80% and 90%. 如果依照衛福部的名詞定義7
[問卦] 為什麼我們買BNT就會一堆問題?實在想不通為什麼我們買BNT就一堆問題 難道只能靠民間捐贈才能買到? 美國都還沒開放莫德納給17歲以下打欸 就算是英國也只是兩天前才通過 而且我看BNT也沒有兒童劑型阿6
Re: [新聞] 新研究發現 抗體濃度可測COVID-19疫苗中央社這篇蠻挑自己想講的出來 裡面有一段: One open question challenging this approach is whether titers to different strains have different relationships with vaccine efficacy. A more challenging objective is bridging vaccine efficacy of new candidate vaccines8
Re: [新聞] 智飛疫苗完成三期 打3劑保護力逾8成很好奇地去查了一些相關資料 Clinical Trial 重點 Phase 3 1. Case Number7
Re: [新聞] 高端疫苗報告等一年 為何遲不公布?保護力不只是確診的保護力,還有住院甚至重症死亡的保護力, 雖然不是隨機分派對照實驗,但新加坡最近發布了一個omicron期間BNT孩童保護力報告 Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
85
[請益] 匯率害台債蛙一頭空怎辦?55
[情報] 7779 鍇睿國際 10/3登錄興櫃33
[標的] 2609 陽明 繼續大獲全勝送錢多38
[請益] 長榮現在還可以買嗎?44
Re: [請益] 老實說現在蓋牌NVDA的人多嗎?18
Re: [心得] 投顧教會我們的事16
[標的] 2412發生了什麼事17
[請益] 為何勞退自提的6%不能開放勞退自選呢?2X
Re: [新聞] 鈊象今年授權收入賺逾一股本10
Re: [新聞] 航海ETF「昨瘋漲今拉回」!00960早盤13
[請益] 新青安對銀行股的影響6
Re: [標的] 大盤X
[請益] 開發金的股票是直接轉成凱基金?X
[標的] 1301 台塑 空4
[標的] 2603長榮 淨值比殖利率多波段當沖都可4
Re: [請益] 為我阿嬤推薦短期震盪劇烈的股票3
有關mags ETF的成份X
[標的] 1799發生什麼事1
[請益] 可轉債申購期間股價已高於轉換價1
Re: [標的] 6177達麗 71波段空 超級空尾盤跌停X
Re: [新聞] 百億遺產之爭2/忍了八年半一吐怨氣